179 related articles for article (PubMed ID: 16556068)
1. Dexrazoxane use in the prevention of anthracycline extravasation injury.
Hasinoff BB
Future Oncol; 2006 Feb; 2(1):15-20. PubMed ID: 16556068
[TBL] [Abstract][Full Text] [Related]
2. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
Hasinoff BB
Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
[TBL] [Abstract][Full Text] [Related]
3. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane: new indication. Anthracycline extravasation: continue using dimethyl sulfoxide.
Prescrire Int; 2009 Feb; 18(99):6-8. PubMed ID: 19382398
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Hasinoff BB; Herman EH
Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
[TBL] [Abstract][Full Text] [Related]
6. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
Langer SW; Thougaard AV; Sehested M; Jensen PB
Cancer Chemother Pharmacol; 2012 Feb; 69(2):573-6. PubMed ID: 22143379
[TBL] [Abstract][Full Text] [Related]
7. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
8. Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.
Frost A; Gmehling D; Azemar M; Unger C; Mross K
Onkologie; 2006 Jul; 29(7):314-8. PubMed ID: 16874015
[TBL] [Abstract][Full Text] [Related]
9. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
10. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
Langer SW; Sehested M; Jensen PB
Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
[TBL] [Abstract][Full Text] [Related]
11. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M
Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798
[TBL] [Abstract][Full Text] [Related]
12. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
Tyson AM; Gay WE
Ann Pharmacother; 2010 May; 44(5):922-5. PubMed ID: 20371757
[TBL] [Abstract][Full Text] [Related]
13. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
14. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.
Kane RC; McGuinn WD; Dagher R; Justice R; Pazdur R
Oncologist; 2008 Apr; 13(4):445-50. PubMed ID: 18448560
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of dexrazoxane.
Hochster HS
Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
[TBL] [Abstract][Full Text] [Related]
16. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
17. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.
Langer SW; Thougaard AV; Sehested M; Jensen PB
Cancer Chemother Pharmacol; 2006 Jan; 57(1):125-8. PubMed ID: 16001176
[TBL] [Abstract][Full Text] [Related]
18. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
Arroyo PA; Perez RU; Feijoo MA; Hernandez MA
J Cancer Res Ther; 2010; 6(4):573-4. PubMed ID: 21358106
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.
Doroshow JH
Curr Pharm Biotechnol; 2012 Aug; 13(10):1949-56. PubMed ID: 22352729
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane for anthracycline extravasation.
Langer SW
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1081-8. PubMed ID: 18028016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
